CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
therapeutics company, announced today that it plans to host its 5th
annual series of “RNAi Roundtable” webcasts this summer. The 2018 series
will offer a range of presentations from Alnylam scientists, clinical
collaborators, and patients or patient advocates, who will review recent
progress in many of the Company’s late-stage pipeline programs and
platform. Each event will be webcast live on the Investors page of the
Company’s website, www.alnylam.com,
and a replay of the roundtables will be posted on the Alnylam website
approximately three hours after each event.
The 2018 RNAi Roundtable schedule will be as follows:
-
Platform Advances in RNAi Therapeutics
Tuesday, June
26, 10:30 am ET
-
Givosiran, in Development for the Treatment of Acute Hepatic
Porphyrias
Tuesday, July 24, 10:00 am ET
-
Lumasiran, in Development for the Treatment of Primary
Hyperoxaluria Type 1
Wednesday, August 15, 10:30
am ET
-
Patisiran & ALN-TTRsc02, for the Treatment of
Transthyretin-Mediated Amyloidosis
Tuesday, September 11,
time TBD
Please visit the Capella
section of our website for the latest information regarding webcast
schedules.
About RNAi
RNAi (RNA interference) is a natural cellular
process of gene silencing that represents one of the most promising and
rapidly advancing frontiers in biology and drug development today. Its
discovery has been heralded as “a major scientific breakthrough that
happens once every decade or so,” and was recognized with the award of
the 2006 Nobel Prize for Physiology or Medicine. By harnessing the
natural biological process of RNAi occurring in our cells, a major new
class of medicines, known as RNAi therapeutics, is on the horizon. Small
interfering RNA (siRNA), the molecules that mediate RNAi and comprise
Alnylam's RNAi therapeutic platform, function upstream of today’s
medicines by potently silencing messenger RNA (mRNA) – the genetic
precursors – that encode for disease-causing proteins, thus preventing
them from being made. This is a revolutionary approach with the
potential to transform the care of patients with genetic and other
diseases.
About Alnylam
Pharmaceuticals
Alnylam (Nasdaq: ALNY) is leading the
translation of RNA interference (RNAi) into a whole new class of
innovative medicines with the potential to transform the lives of people
afflicted with rare genetic, cardio-metabolic, and hepatic infectious
diseases. Based on Nobel Prize-winning science, RNAi therapeutics
represent a powerful, clinically validated approach for the treatment of
a wide range of severe and debilitating diseases. Founded in 2002,
Alnylam is delivering on a bold vision to turn scientific possibility
into reality, with a robust discovery platform and deep pipeline of
investigational medicines, including four product candidates that are in
late-stage development. Looking forward, Alnylam will continue to
execute on its "Alnylam 2020" strategy of building a multi-product,
commercial-stage biopharmaceutical company with a sustainable pipeline
of RNAi-based medicines to address the needs of patients who have
limited or inadequate treatment options. Alnylam employs over 800 people
in the U.S. and Europe
and is headquartered in Cambridge,
MA. For more information about our people, science and
pipeline, please visit www.alnylam.com
and engage with us on Twitter at @Alnylam
or on LinkedIn.